ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2023 and some content may be unavailable. To unlock all content for 2023, please visit the archives.

Abstract: TH-PO965

Hemoglobin (Hgb) Targets in Hemodialysis (HD) Patients: What Is the Optimal Target Range?

Session Information

Category: Anemia and Iron Metabolism

  • 200 Anemia and Iron Metabolism


  • Raimann, Jochen G., Renal Research Institute, New York, New York, United States
  • Mermelstein, Ariella E., Renal Research Institute, New York, New York, United States
  • Kovacevic, Tomislav, Vifor Pharma Management Ltd, Glattbrugg, Zurich, Switzerland
  • Hymes, Jeffrey L., Fresenius Medical Care Holdings Inc, Waltham, Massachusetts, United States
  • Kotanko, Peter, Renal Research Institute, New York, New York, United States

Based on RCTs a hgb target range between 10 to 11 g/dL is mandated in the US. Retrospective analyses have shown lower hospitalization and death rates with higher values. We investigated the association between all-cause mortality hazard ratio (HR) and time spent outside the target range.


We studied incident HD patients (pts) initiated on a long-acting ESA (Mircera; Vifor) within the first 90 days. In pts with at least 12 hgb during the 6-months baseline (BL), we quantified the patient-individual area under the target excursion curve (AUC) ‘above’ and ‘below’ the target range (10 to 11 g/dL). We used these metrices as predictors in proportional hazard models predicting HR in the following 18 months. We fitted the HR as a spline function of mean BL hgb. We built an additional model, adjusted for race, sex, age, diabetes, serum albumin and phosphorus, as spline functions in a bivariate fashion as a function of AUC above and below as a contour plot. Sensitivity analyses considering cumulative ESA doses, iron status, vintage, excursion frequency, nutrition and inflammation were performed.


We studied 64,042 pts out of 517,860 pts. We found a preferable target range to be between 10.3 and 12.2 g/dL (Figure 1). AUC ‘below’ in the presence of low AUC ‘above’ conferred a higher risk of death, whereas a higher AUC “above” only started to increase risk only at around 150 g/dLxdays (Figure 2). Sensitivity analyses did not change the interpretation.


A wider and higher target range associates with more favorable outcomes. Limitations of retrospective research apply. Adequately powered and designed experimental studies are needed.
Figure 1: HR as a function of mean BL hgb levels.
Figure 2: HR as a function of AUC above and below.


  • Commercial Support – Vifor Fresenius Medical Care Pharma Ltd